Can a patient take Paxlovid (nirmatrelvir/ritonavir) concurrently with bupropion?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: April 11, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Can a Patient Take Paxlovid and Bupropion Concurrently?

No, concurrent use of Paxlovid (nirmatrelvir/ritonavir) and bupropion requires significant dose adjustment of bupropion due to a clinically significant drug-drug interaction, and you must carefully weigh whether the COVID-19 treatment benefit outweighs the complexity of managing this interaction.

Understanding the Drug Interaction

The ritonavir component of Paxlovid is a strong CYP3A inhibitor that paradoxically induces CYP2B6, the primary enzyme responsible for bupropion metabolism 1. This creates a problematic interaction:

  • Ritonavir 600 mg twice daily reduces bupropion exposure by 62-67% (both AUC and Cmax) 2
  • Ritonavir 100 mg twice daily (the dose in Paxlovid) reduces bupropion exposure by 21-22% 2
  • The active metabolite hydroxybupropion is also significantly reduced (31-50% decrease) 3

This means bupropion becomes substantially less effective when taken with Paxlovid, potentially leading to loss of therapeutic effect for depression, smoking cessation, or other indications.

Clinical Decision Algorithm

Step 1: Assess COVID-19 Treatment Necessity

  • Is the patient at high risk for COVID-19 progression (hospitalization/death)?
  • Are symptoms within 5 days of onset?
  • If YES to both → Paxlovid has strong evidence for benefit 4, 5
  • If NO → Consider alternative COVID-19 treatments or no antiviral treatment

Step 2: Evaluate Bupropion Indication Urgency

  • For depression/psychiatric indications: Can bupropion be temporarily discontinued for 5 days without significant risk?
  • For smoking cessation: This is typically non-urgent and can be interrupted
  • For seizure risk: Note that bupropion lowers seizure threshold; temporary discontinuation may actually reduce risk during acute illness

Step 3: Management Options

Option A - Preferred if COVID-19 treatment is indicated:

  1. Discontinue bupropion before starting Paxlovid
  2. Complete the 5-day Paxlovid course
  3. Wait at least 3-5 days after completing Paxlovid before restarting bupropion (to allow ritonavir washout)
  4. Resume bupropion at previous dose

Option B - If bupropion cannot be discontinued:

  1. Consider alternative COVID-19 treatments without this interaction:
    • Molnupiravir (though less effective than Paxlovid) 5
    • Remdesivir (requires IV administration) 5
  2. Only use Paxlovid with continued bupropion if COVID-19 risk clearly outweighs psychiatric risk

Option C - If both drugs must continue (NOT recommended):

  1. Increase bupropion dose up to 100% to compensate for reduced exposure 2, 3
  2. Do NOT exceed maximum recommended daily dose of bupropion (450 mg/day for immediate release, 400 mg/day for sustained release, 450 mg/day for extended release) 2
  3. Monitor closely for loss of bupropion efficacy
  4. Return to baseline bupropion dose 3-5 days after completing Paxlovid

Critical Safety Considerations

FDA Black Box Warning

The FDA label explicitly warns that ritonavir may lead to potentially severe, life-threatening, or fatal events from drug interactions 1. While bupropion interaction is not life-threatening in the traditional sense, loss of antidepressant efficacy carries psychiatric risks.

Common Pitfalls to Avoid

  1. Do not simply continue both medications without adjustment - this will result in subtherapeutic bupropion levels
  2. Do not exceed maximum bupropion doses even when compensating for the interaction - seizure risk increases
  3. Do not restart bupropion immediately after Paxlovid - ritonavir has a prolonged effect lasting several days after discontinuation 5
  4. Do not forget to counsel the patient about temporary loss of smoking cessation or antidepressant effect

When to Seek Expert Consultation

Contact clinical pharmacology if 6:

  • Patient has complex psychiatric history where bupropion interruption poses significant risk
  • Patient is on multiple interacting medications
  • Uncertainty exists about the risk-benefit balance

Evidence Quality Note

The interaction data comes from well-designed pharmacokinetic studies in healthy volunteers 2, 3, and the FDA label explicitly addresses ritonavir's role as a "perpetrator of many drug-drug interactions" 1. French pharmacology guidelines classify this as requiring careful management 6. The evidence is clear and consistent: this interaction is real, dose-dependent, and clinically significant.

Practical Implementation

For a typical patient on bupropion 150 mg twice daily who develops COVID-19:

  1. Stop bupropion on day 1
  2. Start Paxlovid on day 1 (if within 5 days of symptoms and high-risk)
  3. Complete 5-day Paxlovid course
  4. Wait until day 9-10 post-COVID diagnosis
  5. Restart bupropion 150 mg twice daily

Document the plan clearly and ensure patient understands the temporary medication change and its rationale.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.